扶正化瘀方对肝癌患者MMP-3和ESM-1表达的影响  

Effect of Fuzheng Huayu Decoction on the Expression of MMP-3 and ESM-1 in Patients with Hepatocellular Carcinoma

作　　者：刘莲[1] 张红霞[1] 陈蕾[1] 崔书彦[1] 张巍[1] 王晨雪[1] 刘琼[1] LIU Lian;ZHANG Hongxia;CHEN Lei;CUI Shuyan;ZHANG Wei;WANG Chenxue;LIU Qiong(The Fifth Hospital of Shijiazhuang City, Shijiazhuang Hebei China 050021)

机构地区：[1]石家庄市第五医院

出　　处：《中医学报》2019年第5期1065-1069,共5页Acta Chinese Medicine

摘　　要：目的:探讨扶正化瘀方治疗原发性肝细胞癌(hepatocellular carcinoma,HCC)中基质金属蛋白酶(matrix metalloproteinase-3,MMP-3)和内皮细胞特异分子-1(endothelial cell specific molecule,ESM-1)的表达及其与患者疾病预后之间的关系。方法:治疗组收集78例HCC患者作为研究对象,并将同时期来本院治疗的60例肝癌患者作为对照组。测定两组MMP-3和ESM-1的表达情况,比较两组阳性率,并分析其扶正化瘀治疗与各病理参数间、MMP-3和ESM-1表达情况的关系及与患者预后的关系。结果:治疗组MMP-3和ESM-1阳性率分别为15.00%和5.00%,对照组阳性率分别为71.79%和76.92%,两组比较,差异有统计学意义(P<0.05)。治疗组MMP-3和ESM-1表达与对照组TNM分期、分化程度和门静脉癌栓有显著差异(P<0.05)。对照组MMP-3和ESM-1患者生存时间和生存率低于治疗组(P<0.01)。结论:治疗组患者MMP-3和ESM-1阳性率显著低于对照组,两组各个TNM分期、分化程度和门静脉癌栓比较有差异。扶正化瘀方可以降低HCC的恶性程度,MMP-3和ESM-1可以作为评估扶正化瘀方治疗HCC患者预后的一项重要指标。Objective:To investigate the expression of matrix metalloproteinase-3(MMP-3) and endothelial cell specific molecule-1(ESM-1) in primary hepatocellular carcinoma(HCC) treated with Fuzheng Huayu Decoction and their relationship with prognosis of patients with HCC.Methods:The treatment group collected 78 cases of HCC patients as the research object,and 60 cases of HCC patients who came to our hospital for other treatment at the same time as the control group.The expression of MMP-3 and ESM-1 in the two groups were measured,and the positive rates were compared.The relationship between the treatment of strengthening the body and removing blood stasis and the pathological parameters,the expression of MMP-3 and ESM-1 and the prognosis of the patients were analyzed.Results:The positive rates of MMP-3 and ESM-1 were 15.00% and 5.00% in the treatment group and 71.79% and 76.92% in the control group,respectively.There was a significant difference between the two groups(P<0.05).The expression of MMP-3 and ESM-1 in Fuzheng Huayu treatment group was significantly different from that in control group in TNM stage,differentiation degree and portal vein cancer thrombus(P<0.05).The survival time and survival rate of MMP-3 and ESM-1 patients in the control group were lower than those in the Fuzheng Huayu treatment group(P<0.01).Conclusion:The positive rates of MMP-3 and ESM-1 in the Fuzheng Huayu treatment group were significantly lower than those in the control group.There were differences between the two groups in TNM stage,differentiation degree and portal vein cancer thrombus.Fuzheng Huayu Decoction can reduce the malignant degree of HCC.MMP-3 and ESM-1 can be used as an important index to evaluate the prognosis of patients with HCC treated by Fuzheng Huayu Decoction.

关 键 词：肝癌 扶正化瘀方 MMP-3 ESM-1 

分 类 号：R273.357[医药卫生—中西医结合]